関連ニュース

Analysts cut price targets and reduced their estimates for azetukalner's psychiatric commercial opportunity after Xenon Pharmaceuticals disclosed an enrollment pause in its Phase 3 depression trials -

Azetukalner's focal-seizure application gives Xenon Pharmaceuticals Inc. a potential path to its first commercial revenues, subject to FDA approval. The psychiatry setback weakens expansion potential,

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

U.S. stock futures were higher this morning, with the Nasdaq 100 futures gaining around 150 points on Friday.

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript